1887

Abstract

. The remarkable intrinsic resistance of species to most antifungal agents results in high mortality rates in the immunocompromised population.

. This study aimed to investigate the epidemiology, clinical features and antifungal susceptibility of isolates in patients with invasive fusariosis.

. A total of 27 patients admitted to a referral hospital from January 2008 to June 2017 were evaluated. Antifungal susceptibility testing of isolates was performed by broth microdilution according to the Clinical and Laboratory Standards Institute guidelines.

. Haematological malignancy was the predominant underlying condition, with an incidence of invasive fusariosis of 14.8 cases per 1000 patients with acute lymphoid leukaemia and 13.1 cases per 1000 patients with acute myeloid leukaemia. The species complex (FSSC) was the most frequent agent group, followed by the species complex (FOSC). Voriconazole showed the best activity against , followed by amphotericin B. Itraconazole showed high minimum inhibitory concentration values, indicating resistance. Clinical FSSC isolates were significantly (<0.05) more resistant to amphotericin B and voriconazole than FOSC isolates.

. The present antifungal susceptibility profiles indicate a high incidence of fusariosis in patients with haematological malignancy. Species- and strain-specific differences in antifungal susceptibility exist within in this setting.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001059
2019-10-01
2019-10-15
Loading full text...

Full text loading...

References

  1. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA et al. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine 201;92:305–316
    [Google Scholar]
  2. Migheli Q, Balmas V, Harak H, Sanna S, Scherm B et al. Molecular phylogenetic diversity of dermatologic and other human pathogenic fusarial isolates from hospitals in northern and central Italy. J Clin Microbiol 2010;48:1076–1084 [CrossRef]
    [Google Scholar]
  3. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004;10 Suppl 1:67–75 [CrossRef]
    [Google Scholar]
  4. Varon AG, Nouer SA, Barreiros G, Trope BM, Magalhães F et al. Superficial skin lesions positive for Fusarium are associated with subsequent development of invasive fusariosis. J Infect 2014;68:85–89 [CrossRef]
    [Google Scholar]
  5. van Diepeningen AD, Al-Hatmi AMS, Brankovics B, de Hoog GS. Taxonomy and clinical spectra of Fusarium species: where do we stand in 2014?. Curr Clin Microbiol Rep 2014;1:10–18 [CrossRef]
    [Google Scholar]
  6. Calado NB, Sousa F, Gomes NO, Cardoso FR, Zaror LC et al. Fusarium nail and skin infection: a report of eight cases from natal, Brazil. Mycopathologia 2006;161:27–31 [CrossRef]
    [Google Scholar]
  7. Al-Hatmi AMS, Hagen F, Menken SBJ, Meis JF, de Hoog GS. Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015. Emerg Microbes Infect 2016;5:1–11 [CrossRef]
    [Google Scholar]
  8. Tortorano AM, Prigitano A, Esposto MC, Arsic Arsenijevic V, Kolarovic J et al. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur J Clin Microbiol Infect Dis 2014;33:1623–1630 [CrossRef]
    [Google Scholar]
  9. Dalyan Cilo B, Al-Hatmi AMS, Seyedmousavi S, Rijs AJMM, Verweij PE et al. Emergence of fusarioses in a university hospital in turkey during a 20-year period. Eur J Clin Microbiol Infect Dis 2015;34:1683–1691 [CrossRef]
    [Google Scholar]
  10. Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010;54:4446–4450 [CrossRef]
    [Google Scholar]
  11. Drogari-Apiranthitou M, Mantopoulou F-D, Skiada A, Kanioura L, Grammatikou M et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother 2012;67:1937–1940 [CrossRef]
    [Google Scholar]
  12. Al-Hatmi AMS, Bonifaz A, de Hoog GS, Vazquez-Maya L, Garcia-Carmona K et al. Keratitis by Fusarium temperatum, a novel opportunist. BMC Infect Dis 2014;14:588 [CrossRef]
    [Google Scholar]
  13. Al-Hatmi AMS, Meis JF, de Hoog GS. Fusarium: molecular diversity and intrinsic drug resistance. PLoS Pathog 2016;12:e1005464–1005468 [CrossRef]
    [Google Scholar]
  14. Jossi M, Ambrosioni J, Macedo-Vinas M, Garbino J. Invasive fusariosis with prolonged fungemia in a patient with acute lymphoblastic leukemia: case report and review of the literature. Int J Infect Dis 2010;14:e354–e356 [CrossRef]
    [Google Scholar]
  15. van Diepeningen AD, Brankovics B, Iltes J, van der Lee TAJ, Waalwijk C. Diagnosis of Fusarium Infections: Approaches to Identification by the Clinical Mycology Laboratory. Curr Fungal Infect Rep 2015;9:135–143 [CrossRef]
    [Google Scholar]
  16. Al-Hatmi AMS, van Diepeningen AD, Curfs-Breuker I, de Hoog GS, Meis JF. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother 2015;70:1–4
    [Google Scholar]
  17. De PB, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of Cancer/Invasive. Clin Infect Dis 2008;46:1813–1821
    [Google Scholar]
  18. Dallé da Rosa P, Nunes A, Borges R, Batista B, Meneghello Fuentefria A et al. In vitro susceptibility and multilocus sequence typing of Fusarium isolates causing keratitis. Journal de Mycologie Médicale 2018;28:482–485 [CrossRef]
    [Google Scholar]
  19. Espinel-Ingroff A, Colombo AL, Cordoba S, Dufresne PJ, Fuller J et al. International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for Fusarium species identified by molecular methods for the CLSI broth microdilution method. Antimicrob Agents Chemother 2016;60:1079–1084 [CrossRef]
    [Google Scholar]
  20. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 2018;35:1547–1549 [CrossRef]
    [Google Scholar]
  21. Wayne P. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, M38-A. 2008;22
  22. Herkert PF, Al-Hatmi AMS, de Oliveira Salvador GL, Muro MD, Pinheiro RL et al. Molecular Characterization and Antifungal Susceptibility of Clinical Fusarium Species From Brazil. Front Microbiol 2019;10:1–11 [CrossRef]
    [Google Scholar]
  23. Scheel CM, Hurst SF, Barreiros G, Akiti T, Nucci M et al. Molecular analyses of Fusarium isolates recovered from a cluster of invasive mold infections in a Brazilian hospital. BMC Infect Dis 2013;13:1–12 [CrossRef]
    [Google Scholar]
  24. Moretti ML, Busso-Lopes AF, Tararam CA, Moraes R, Muraosa Y et al. Airborne transmission of invasive fusariosis in patients with hematologic malignancies. PLoS One 2018;13:e0196426–13 [CrossRef]
    [Google Scholar]
  25. Garnica M, Nucci M. Epidemiology of fusariosis. Curr Fungal Infect Rep 2013;7:301–305 [CrossRef]
    [Google Scholar]
  26. Nucci M, Varon AG, Garnica M, Akiti T, Barreiros G et al. Increased incidence of invasive fusariosis with cutaneous portal of entry, Brazil. Emerg Infect Dis 2013;19:1567–1572 [CrossRef]
    [Google Scholar]
  27. Nir-Paz R, Strahilevitz J, Shapiro M, Keller N, Goldschmied-Reouven A et al. Clinical and epidemiological aspects of infections caused by Fusarium species: a collaborative study from Israel. J Clin Microbiol 2004;42:3456–3461 [CrossRef]
    [Google Scholar]
  28. Azor M, Gené J, Cano J, Manikandan P, Venkatapathy N et al. Less-frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility. J Clin Microbiol 2009;47:1463–1468 [CrossRef]
    [Google Scholar]
  29. Liu Y-S, Wang N-C, Ye R-H, Kao W-Y. Disseminated Fusarium infection in a patient with acute lymphoblastic leukemia: A case report and review of the literature. Oncol Lett 2014;7:334–336 [CrossRef]
    [Google Scholar]
  30. Rosa PD, Heidrich D, Corrêa C, Scroferneker ML, Vettorato G et al. Genetic diversity and antifungal susceptibility of Fusarium isolates in onychomycosis. Mycoses 2017;60:616–622 [CrossRef]
    [Google Scholar]
  31. Al-Hatmi AMS, Bonifaz A, Ranque S, Sybren de Hoog G, Verweij PE et al. Current antifungal treatment of fusariosis. Int J Antimicrob Agents 2018;51:326–332 [CrossRef]
    [Google Scholar]
  32. Al-Hatmi AMS, Bonifaz A, Tirado-Sánchez A, Meis JF, de Hoog GS et al. Fusarium species causing eumycetoma: Report of two cases and comprehensive review of the literature. Mycoses 2017;60:204–212 [CrossRef]
    [Google Scholar]
  33. Taj-Aldeen SJ, Salah H, Al-Hatmi AMS, Hamed M, Theelen B et al. In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method. Diagn Microbiol Infect Dis 2016;85:438–443 [CrossRef]
    [Google Scholar]
  34. Guarro J, Fusariosis GJ. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis 2013;32:1491–1500 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001059
Loading
/content/journal/jmm/10.1099/jmm.0.001059
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error